Prostate

Androgen deprivation therapy sequencing had a considerable effect on outcomes among men with prostate cancer who received prostate-only radiotherapy, according to study results published in Journal of Clinical Oncology.

Prostate cancer clinical trials included significant underrepresentation of Asian, Black and Hispanic men based on incidence of the disease among these groups, results of meta-analysis published in JAMA Oncology showed.

In this video, Kara N. Babaian, MD, spoke with Healio about a presentation on patient-reported outcomes after radical prostatectomy for high-risk prostate cancer from the American Urological Association meeting.

In this video, Eugene Shenderov, MD, PhD, discusses the STAMPEDE and PEACE-1 studies, which evaluated the addition of abiraterone acetate plus prednisolone to standard therapy for patients with prostate cancer.

In this video Kevin B. Ginsburg, MD, a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, discusses abstracts looking at focal therapy and active surveillance for prostate cancer patients presented at the American Urological Association's annual meeting.

In this video Sandeep Gurram, MD, a urologic oncologist at the National Cancer Institute in Bethesda, Maryland, discusses a study on the novel diagnostic tool, the miR Sentinel PCC4 Test, presented at the American Urological Association's annual meeting.

In this video, Stacy Loeb, MD, professor in the department of urology at NYU Grossman School of Medicine, discusses studies looking at genetic counseling and its effect on the management of advanced prostate cancer.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses two posters on prostate cancer therapies presented at the ESMO Congress 2021.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses a phase I/II multicenter first-in-human trial of DS-7300, an anti-B7-H3, which was studied in patients with advanced solid tumors.

In this video, Alicia K. Morgans, MD, discusses a study on the clinical and cost impact of cabazitaxel vs. a second androgen receptor targeted agent for patients with metastatic castration-resistant prostate cancer.